Amgen Highlights The Latest EVENITY ™ (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting

First Presentation of Detailed EVENITY ARCH Study Results and FRAME Extension Final Analysis 10-Year Data From Long-Term Prolia FREEDOM Study THOUSAND OAKS, Calif., Sept. 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and Prolia® (denosumab) at this year's Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Denver from Sept. 8-11, 2017. "The data being presented at ASBMR underscore our steadfast focus for more than a decade to advance scientific understanding and care for the millions of people living with osteoporosis," said Sean E. Harper...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news